

Chief Complaint (CC)**Date: December 2015**

75 y/o male began showing evidence of disease progression

History of Present Illness (HPI)

Pt initially presented with ISS stage 3 IgG lambda multiple myeloma with no high-risk features in June 2011

- Received induction lenalidomide, bortezomib and dexamethasone (RVd) induction for 4 cycles
- Pt experienced G3 peripheral neuropathy, requiring bortezomib dose-reduction in cycle 4

Pt received ASCT in December 2011, achieving VGPR

- Started lenalidomide maintenance in September 2012
- Demonstrated symptomatic relapse in June 2014

Pt initiated RVd again as second-line therapy in June 2014

- Lenalidomide dose was increased from maintenance to 25 mg D1-21 q28d
- Showed signs of disease progression and worsening peripheral neuropathy 6 months later

Pt switched to carfilzomib and dexamethasone (Kd) in December 2014

- Pt achieved PR and continued therapy for 1 yr

Pt demonstrated evidence of disease progression in December 2015

- Continues to have stable G2 peripheral neuropathy, and receives supportive care